A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer|Advanced Solid Tumor
Interventions: DRUG: ADG106|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel
Sponsor: National University Hospital, Singapore
Collaborators: Adagene Inc